Cours suspendu

Communiqués TOUE BIOPAR

Actions

TRML

US89157D1054

Marché Fermé - NYSE 21:00:00 27/10/2025			Varia. 5j.	Varia. 1 janv.
47,98 ^USD	-.--%		-.--%	-

28/10/25	L'indice suisse SMI termine en baisse, Novartis recule	MT
28/10/25	Novartis finalise l'acquisition du groupe biopharmaceutique américain Tourmaline Bio	MT

Communiqués

06/10/25	Tourmaline Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRML	BU
11/09/25	TOURMALINE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRML	BU
09/09/25	Novartis expands in cardiovascular disease with $1.4bn Tourmaline Bio acquisition	AQ
09/09/25	Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG	AQ
31/08/25	Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress	AQ
13/08/25	Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights	AQ
20/05/25	Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease	AQ
19/05/25	Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025	AQ
02/05/25	Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights	GL
13/03/25	Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights	AQ
03/03/25	Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025	AQ
27/01/25	Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference	AQ
10/01/25	Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker	AQ
10/12/24	Tourmaline Bio : Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day Form 8 K	PU
10/12/24	Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day	AQ
14/11/24	Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024	AQ
07/11/24	Tourmaline Bio : Reports Third Quarter 2024 Financial Results and Recent Business Highlights Form 8 K	PU
07/11/24	Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights	AQ
31/10/24	Tourmaline Bio to Present at Upcoming Investor Conferences	AQ
15/10/24	Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024	AQ
11/10/24	Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress	AQ
08/10/24	Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board	AQ
03/09/24	Tourmaline Bio to Present at Upcoming Investor Conferences	GL
08/08/24	Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights	GL
02/08/24	Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024	GL